The advent of effective treatments for non-small cell lung cancer directed at increasingly well-characterized genetic and immunologic targets has resulted in significant gains in survival; trials are ongoing. As our knowledge of tumor driver mutations and immune evasion strategies rapidly expands, so does the need for extensive characterization of tumor cells by multiple. methods. Additionally, less invasive biopsy techniques are commonly used; Cytopathologists are thus asked to do more and more with smaller samples. Discussion will include strategies for specimen triage and algorithms for testing.
- Provider:American Society of Cytopathology
- Activity Link: https://education.cytopathology.org/
- Start Date: 2024-07-23 05:00:00
- End Date: 2024-07-23 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- MOC Credit Details: ABPATH - 2.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Cytopathology
Subscribe
Login
0 Comments
Oldest